Utpal Bhui

Utpal Bhui

PhD Research Scholar

Lovely Professional University

Profile ID RP-003-2203 Joined 2025-03-31 2 articles
0Connections
6
Total Views
2
Total Publications
36
Publication Views

About me

I am PhD Research Scholar at School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab-144411.

Articles(2)

Authors: Subhajit Sarkar, Utpal Bhui, Bimlesh Kumar, Sumel Ashique, Prashant Kumar, Himanshu Sharma, Mithun Bhowmick, Radheshyam Pal, Tinku Kumar

DOI: 10.2174/0126660822329981241007105405

Volume21
Issue0
Pages0
Abstract

Abstract: The correlation between elevated levels of amyloid-β and phosphorylated tau (p-tau) protein and AD is widely recognized. A rise in pTau and amyloid- β levels aids in separating AD from other neurodegenerative conditions. In this study, we have assessed the correlation between cognitive impairment and peripheral biomarkers, tau and amyloid-β levels, in AD patients with mild Alzheimer's disease in order to develop protein-based markers in a more useful way. An enzyme-linked immunosorbent assay has been used to determine the levels of tau and p-tau in the serum of the different groups and it has revealed their levels to be noticeably greater in AD compared to mild AD and even higher compared to elderly controls. Based on the cutoff levels for tau, p-tau, and amyloid-β in patients with AD and mild AD, having high sensitivity and specificity, which have been described in numerous studies by respective International Research Groups (with the greatest number of pieces of available evidence), the plasma concentration of these proteins can be used as a diagnostic indicator for AD and mild AD. These levels may also offer a practical guide to their implementation in the clinical routine.

Authors: Sabina Yasmin, Sumel Ashique, Tahreen Taj, Ashish Garg, Joy Das, Eman Shorog, Utpal Bhui, Radheshyam Pal, Samy Selim, Uttam Prasad Panigrahy, Naseem Begum, Anas Islam, Mohammad Yousuf Ansari

DOI: 10.1016/j.brainres.2024.149400

Volume1850
Issue0
Pages149400
Abstract

Hypertension poses a significant risk to cognition-related disorders like dementia. As the global population ages, age-related neurological illnesses such as Alzheimer’s disease are becoming increasingly prevalent. The primary hypertension treatments, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors, exhibit neuroprotective properties. However, observational studies suggest that they may independently contribute to cognitive decline and dementia. Some of these medications have shown promise in reducing cognitive impairment and amyloid buildup in Alzheimer’s models. While direct comparisons between the two drug classes are limited, angiotensin receptor blockers have been associated with less brain shrinkage, lower dementia incidence, and slower cognitive decline compared to angiotensin-converting enzyme inhibitors. Both types of medications can influence cognition by passing the blood–brain barrier, with angiotensin receptor blockers potentially offering superior neuroprotective effects due to their selective blockade of the angiotensin type 1 receptor.

No matching articles

Try another word from the title, author or DOI.

Brief Bio

I am PhD Research Scholar at School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab-144411.

Affiliations

Nothing added yet.

Education

Nothing added yet.

Honors & Awards

Nothing added yet.

Society Memberships

Nothing added yet.

Expertise

Nothing added yet.

Specialty

Nothing added yet.

Scholars in the same field

CM
Carol Mary Koshy
0 publications
VK
Vinay Kumar
0 publications
NN
Nilam Navinbhai Pala
0 publications
SK
Surendra Kumar Pal
0 publications
HP
Himanshu Pandey
0 publications
SR
SHUBHRA RAMCHANDANI
0 publications
AR
Ananta Raj Sharma
0 publications
PM
Dr Payal Mate
0 publications

Following

Nobody here yet.

Followers

Nobody here yet.

2 Publications

0 Contributions

Nothing added yet.

Filter